iSpecimen (ISPC) vs MaxCyte (MXCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
MaxCyte is the larger company by market cap ($141.5 million vs $2.6 million), about 53.5 times the size. MaxCyte converts more of its revenue into profit, with a net margin of -135.1% versus -543.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ISPC | MXCT |
|---|---|---|
| Share price | $0.4563 | $1.37 |
| Market cap | $2.64M | $141.45M |
| 1-day change | -13.58% | +7.03% |
| YTD return | — | -11.61% |
| 1-year return | — | -17.96% |
| 5-year return | — | -85.92% |
| EPS (TTM) | $-52.98 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.93M | $33.03M |
| Revenue growth (YoY) | -79.24% | -14.50% |
| Net income (latest FY) | $-10.49M | $-44.63M |
| Gross margin | 11.18% | 81.16% |
| Operating margin | -465.42% | -157.14% |
| Net margin | -543.68% | -135.14% |
| 52-week high | $27.44 | $1.80 |
| 52-week low | $0.432 | $0.643 |
| Distance from 52-week high | -98.34% | -23.89% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +200.00% |
| Average volume | 598.66K | 1.04M |
| Shares outstanding | 5.79M | 103.25M |
| Employees | 7 | 91 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MaxCyte is about 53.5 times larger than iSpecimen by market value ($141.45M vs $2.64M).
- MaxCyte is more profitable, keeping -135.1 cents of every revenue dollar as net income versus -543.7 cents for iSpecimen.
- MaxCyte grew revenue faster in its latest fiscal year (-14.50% vs -79.24%).
About iSpecimen
ISPC stock →iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 7 employees
About MaxCyte
MXCT stock →MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 91 employees
ISPC vs MXCT FAQ
Which is bigger, iSpecimen or MaxCyte?
MaxCyte (MXCT) is larger, with a market capitalization of $141.45M compared with $2.64M for iSpecimen (ISPC).
Are iSpecimen and MaxCyte in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.